Use of low free to total PSA ratio in prostate cancer screening: detection rates, clinical and pathological findings in Brazilian men with serum PSA levels <4.0 ng/mL

Abstract

E 6 5 3What ' s known on the subject? and What does the study add? In spite of its low specifi city, PSA is the most widely used screening test for prostate cancer (PCa), and is considered the main cause of the stage migration recently observed. The ratio of free to total PSA (%fPSA) has been shown to increase PSA accuracy in cancer detection; however, few screening studies have systematically evaluated its role in cancer detection rates in men with PSA levels < 4.0 ng/mL and normal DRE.The present study supports a possible role of %fPSA as an adjunct to screening in men with total PSA 2.5 -4.0 ng/mL and normal DRE, with a marked increase in cancer detection rates in a large Brazilian PCa screening study. We believe that %fPSA maybe a useful refi nement to biopsy indications in men with low PSA levels. OBJECTIVE• To evaluate the role of the free to total prostate-specifi c antigen ratio (%fPSA) in identifying prostate cancer (PCa) in men with a prostate-specifi c antigen (PSA) level of 2.5 -3.9 ng/mL and a normal digital rectal examination (DRE). PATIENTS AND METHODS• A prospective PCa screening study was conducted, which included 17 571 men aged ≥ 45 years, across six Brazilian states, where men were recalled for further evaluation in the case of either a suspicious DRE and/or PSA ≥ 4.0 ng/mL, or PSA 2.5 -3.9 ng/mL and %fPSA ≤ 15.• We evaluated the impact of a %fPSA ≤ 15 on cancer detection rates and the clinical and pathological stage of tumours in men with a normal DRE and PSA 2.5 -3.9 ng/mL. RESULTS• When suspicious DRE and/or PSA ≥ 4.0 ng/mL were considered as criteria to prompt further evaluation, the cancer detection rate was 3.1%. When %fPSA ≤ 15 in men with total PSA levels of 2.5 -3.9 ng/ mL were considered as criteria, the PCa detection rate increased to 3.7%. Considering %fPSA ≤ 15 in men with PSA 2.5 -3.9 ng/mL and normal DRE, the positive predictive value of biopsy was 31.1%.• Clinical stage was more favourable among men with PSA 2.5 -3.9 ng/mL, normal DRE, and %fPSA ≤ 15 compared with men with normal DRE and PSA ≥ 4.0 ng/mL ( P = 0.02).• Among those who underwent radical prostatectomy, pathological stage and the proportion of insignifi cant tumours were similar between men with PSA 2.5 -3.9 ng/mL, normal DRE fi ndings and %fPSA ≤ 15, and men with PSA ≥ 4.0 ng/mL. CONCLUSIONS• The use of %fPSA ≤ 15 as a biopsy indication in men with normal DRE and PSA 2.5 -4.0 ng/mL in a PCa screening programme, increased cancer detection rates. Tumours in this subset of patients had similar pathological characteristics.• Using %fPSA ≤ 15 to indicate biopsy in men with PSA 2.5 -3.9 ng/mL is a useful adjunct to PCa screening. Use of low free to total PSA ratio in prostate cancer screening: detection rates, clinical and pathological fi ndings in Brazilian men with serum PSA levels < 4.0 ng/mL

Prostate-Specific Antigen testing in men between 40 and 70 years in Brazil: database from a check-up program

“…All patients had clinical stage I and 96.8% had Gleason score ≤ 7. After radical prostatectomy, 82.4% had pathological stage T2 and 17.6% had pathological stage T3 (20). In our study we have found similar results regarding prostate biopsy predictive positive value.…”

The Hospital de Câncer de Barretos Registry: an analysis of cancer survival at a single institution in Brazil over a 10-year period

“…Prevention programmes carried out by the Brazilian Government are mostly opportunistic and Hospital de Câncer de Barretos is one of the proponents institutions of prevention programs for skin cancer [11], cervix, prostate [12,13] and breast cancer [14] recognized in the country. The effectiveness of these programs is perceived through the large number of patients recruited from around the country that are sent to the institution for clinical and complementary examination and specialized treatment.…”

Prostate cancer screening among elderly men in Brazil: should we diagnose or not?

“…We performed an analysis on the database of the Mobile Cancer Prevention Units (MCPU) program (14), which visited 231 cities of six Brazilians states between 2004 and 2007, including 17.571 volunteers for PSA-based PCa screening, aged ≥45 years. There was no upper age cut-off on those willing to volunteer, as reported by Faria et al (14,17,18).…”

“…The criteria for prostate biopsy were: suspicious digital rectal examination (DRE) findings, or PSA >4.0ng/ml, or PSA 2.5-4.0ng/ml with free/total PSA ratio ≤15% (which was performed to assess the increase in the PCa detection rate in one preliminary study of the MCPU program, when the literature lacked data to the date) (18).…”